Rapamycin (Sirolimus) Licensed by Pfizer

Catalog No.S1039

Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Price Stock Quantity  
USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Inquiry

Massive Discount Available

Free Overnight Delivery on all orders over $ 500.

Rapamycin (Sirolimus) Chemical Structure

Rapamycin (Sirolimus) Chemical Structure
Molecular Weight: 914.18

Validation & Quality Control

Cited by 62 publications:

12 customer reviews :

Quality Control & MSDS

Related Compound Libraries

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Product Information

  • Compare mTOR Inhibitors
    Compare mTOR Products
  • Research Area
  • Combination Therapy
    Combination Therapy

Product Description

Biological Activity

Description Rapamycin (Sirolimus) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets mTOR [1]
(HEK293 cells)
IC50 ~0.1 nM
In vitro Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell LinesAssay TypeConcentrationIncubation TimeFormulationActivity DescriptionPMID
HT-29M1;aemN6fG:2b4jpZ{BCe3OjeR?=MXexNEBvVQ>?NVzZNoxyPzJiaB?=NV[2e5JrTE2VTx?=MUXQc5RmdnSrYYTld{Bk[W2ydH;0bIVkcW5vaX7keYNm\CCleYTveI95cWOrdIm=NYDKeYVJOjR7MEC4O|M>
HT-29MU\DfZRwfG:6aXOgRZN{[Xl?MoPhNVAhdk1?M4XBV|czKGh?NELFd|NFVVORMUTQc5RmdnSrYYTld{BlcWerdH;4bY4ucW6mdXPl[EBkgXSxdH;4bYNqfHl?MYCyOFkxODh5Mx?=
HT-29NUPtSVZWS3m2b4TvfIlkKEG|c3H5Mn;PNVAhdk1?NX7PTGJ{PzJiaB?=NHm0dYZFVVORNHvlTXRRd3SnboTpZZRmeyB3LX\seY9zd3W{YXPpcE1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>?MWKyOFkxODh5Mx?=
PC3M3L6cWtqdmG|ZTDBd5NigQ>?MVWxNFAhdk1?MVqxJIg>NHLOfFJFVVORMlzOVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFwyOCCwTT6=MonWNlE6Pzh4OEO=
PC3MWrLbY5ie2ViQYPzZZk>M37ZZVExOCCwTR?=NUTlfXRSOSCqNWiyZ2xtTE2VTx?=NXLFdYZ4TG:nczDuc5QhcW6qaXLpeEBuXE:ULX3l[IlifGWmIFHreEBxcG:|cHjvdplt[XSrb36=NGTzVVIzOTl5OE[4Ny=>
PC3M2jCbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1:xdVEvPSEQvF2=NVfkc3pbOSCqNYfiOG9lTE2VTx?=MWLJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RiaIXtZY4hWEN|IHPlcIx{KHerdHigTWM2OCCxZjC8NVAhdk1?NIjTcoczOTl5OE[4Ny=>
HEK293MXLGeY5kfGmxbjDBd5NigQ>?MVmxNFAhdk1?NFTjVWs5KGh?MYXEUXNQNFfjO2RKdmirYnn0d{BVWEFvaX7keYNm\CCmZXfyZYRifGmxbjDv[kBR\GOmNDD3bZRpKEWFNUCgc4YhPTBibl2=MXiyNVU{QTNyMR?=
BT-20NFzMSG5McW6jc3WgRZN{[Xl?NXL2bGZLOjBizszNMY\EUXNQNGHIUnZFd2W|IH7veEBqdmirYnn0JI1VV1KFMjDk[ZBmdmSnboSgdGFsXCCVNEezJJBpd3OyaH;yfYxifGmxbh?=MXiyNVM2OzV3MR?=
U937MWfBcpRq[mGldHXybYFtKEG|c3H5Mm\VOVAh|ryPMoPVOFghcA>?NXPFOJhpTE2VTx?=NFHPbo1KdmS3Y3XzJIFvfGmkYXP0[ZJq[WxiYXP0bZZqfHliYXfhbY5{fCC5aXzkJJR6eGViTHXnbY9v\WyuYTDwcoV2dW:yaHnsZUBRcGmuYXTlcJBpcWFvMTDKVlMzKGmwIGW5N|ch[2WubIO=NXPQ[oNmOjFzNEKxNFY>
U937MX\BcpRq[mGldHXybYFtKEG|c3H5MY[1NEDPxE1?NGTkdpI1QCCqNGTPVnZFVVORNEL0SnVFd2W|IH7veEBqdmS3Y3WgZY51cWKjY4TldolidCCjY4Tpeol1gSCjZ3HpcpN1KE2LUDDwdo91\WmwLXTl[olkcWWwdDDM[Ydqd26nbHzhJJBv\XWvb4DobYxiKEqUM{KtNkBqdiCXOUO3JINmdGy|NWDCd5E{OjFzNEKxNFY>
U937M1q3W2FvfGmkYXP0[ZJq[WxiQYPzZZk>NGX0Om82OCEQvF2=M3jmd|Q5KGh?M3XOUmROW09?MmjESI9meyCwb4SgbY5lfWOnIHHueIlj[WO2ZYLpZYwh[WO2aY\peJkh[WejaX7zeEBGe2OqZYLpZ4hq[SClb3zpJGhDOTBzIHnuJHU6OzdiY3XscJM>Ml[xNlEyPDJzME[=
MCF-7MXHBeZRweGijZ4mgRZN{[Xl?NELoWHo{OCCwTR?=M375fFQhcA>?NHrNOHdFVVORMVHJcoR2[2W|IHH1eI9xcGGpeR?=NHnB[nIzODB{OEGzOC=>
U87MGNXfWUm9XU2mwYYPlJGF{e2G7M1[1cFEh|ryPNIjucIc3KGh?MkL1SG1UVw>?MX7Qc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdg>?M{PINlE6QDR6NEC0
U87MGMkixT4lv[XOnIFHzd4F6NIO3RWYyKM7:TR?=NGLYT|Q3KGh?M4Kz[WROW09?Ml3qVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36=NYfRb|dqOTl6NEi0NFQ>
U87MGM33HTmtqdmG|ZTDBd5NigQ>?NYO4cohoOSEQvF2=MV:2JIg>MlPPSG1UVw>?NIHae5VFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?=MXKxPVg1QDRyNB?=
U87MGNUD1dolJU2mwYYPlJGF{e2G7M2HGVVEh|ryPNWOzRnhsPiCqM3;GO2ROW09?MVLEc4V{KG6xdDDpcohq[mm2IGCtOGVDWDFqVEO3M|Q3MSCyaH;zdIhwenmuYYTpc44>MYKxPVg1QDRyNB?=
COS7 cells expressing EGFP-HDQ74/rhebM{DqNWF2fG:yaHHnfUBCe3OjeR?=M1\kOFAvOiEQvF2=M{\wOlI1KGh?M{TF[GROW09?M{DIVmlv\HWlZYOgZZV1d3CqYXf5NH7CVnkyQDN7MUm0PS=>
COS7 cells expressing EGFP-LC3M13SRWF2fG:yaHHnfUBCe3OjeR?=NXvF[WJiOC5{IN88US=>MV6yOEBpNV7Vc2lOTE2VTx?=NFXIWnVKdmS3Y3XzJIF2fG:yaHHnfS=>Mn;NNVg{QTF7NEm=
H4MlW2SpVv[3Srb36gRZN{[Xl?NXXQe4txOC5{IN88US=>NEHadFEzPCCqM3TqOWROW09?NUHn[opDUW6lcnXhd4V{KHSqZTDyZZRqdyCxZjDsbYdpfCClaHHpckA{KHO3YoXubZQhOiC2bzDsbYdpfCClaHHpckA{KHO3YoXubZQhOSCrbjDoeY1idiCKNDDj[Yxtew>?NYXMOZJXOThyMkS1PFQ>
HeLaM2LKUGZ2dmO2aX;uJGF{e2G7MXyxNFAhdk1?MnTCN|YhcA>?MVfEUXNQMmnLTY5lfWOnczDGVmIhUzJyOUXQMEBVOjB7OFysJHczOTBzRjDteZRidnRvdXLpdZVqfGmwQzDpcpRmemGldHnvci=>NGrISIEyPzV4M{O4OS=>
HeLaM4HPUmZ2dmO2aX;uJGF{e2G7M4DNW|ExOCCwTR?=NW[1dlhKOzZiaB?=Mk\VSG1UVw>?M2j4R2lv\HWlZYOgSnJDKFd{MUCxSkBufXSjboSteYJqeXWrdHnuR{BqdnSncnHjeIlwdg>?MlnlNVc2PjN|OEW=
HeLaNEDaU2lHfW6ldHnvckBCe3OjeR?=M3L3[FExOCCwTR?=MmTSN|YhcA>?NEDyWY1FVVORMmHGTY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;uNX\Mbo1{OTd3NkOzPFU>
SYFMUfGeY5kfGmxbjDBd5NigQ>?M{jwVlExOCCwTR?=NFGzdXUzPCCqMWDEUXNQM2ryTGlv\HWlZYOgSnJDNU[NQmCgZ49ueGyneDDpcpRmemGldHnvci=>NIfvfZoyPzV4M{O4OS=>
SYFM4rnUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWTFU4pEOTByIH7NMWGyOEBpMlPQSG1UVw>?M2TUOGlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDTXWYh[2WubIO=NIrjZ5AyPzV4M{O4OS=>
HEK293TMnjBRY51cX[rcnHsJGF{e2G7MYmxJI5OMUi0JIQ>M3PSW2ROW09?MVLJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhWjVid3n0bEBGSzVyIH;mJFAvOSCwTR?=MXOxO|Q5PTVyMR?=
HEK293TMmD2RY51cX[rcnHsJGF{e2G7M1;1VVEhdk1?MUC0JIQ>NEjEemRFVVORMXjJcoR2[2W|IHHueIl3cXKjbDDhZ5Rqfmm2eTDh[4FqdnO2IFjJWlEhYDRid3n0bEBGSzVyIH;mJFAvOyCwTR?=NGnvSHUyPzR6NUWwNS=>
PBMCM4nKcGZ2dmO2aX;uJGF{e2G7M3W3UlEhdk1?NYrMXnY{OTRiZB?=NWL0NY5JTE2VTx?=NXzyWmhEWmWmdXPld{BES1J3IHTlcpNqfHl?M{DaelE4PDh3NUCx
PBMCMUTGeY5kfGmxbjDBd5NigQ>?NHvLVmgyKG6PNEfENHYyPCCmM3vHfmROW09?MUfEc4V{KG6xdDDh[oZm[3RiQ2jDVlQh\GWwc3n0fS=>MW[xO|Q5PTVyMR?=
HEK293 cellsMlvDT4lv[XOnIFHzd4F6NUPxT3hWPTBibl2=MkX4OFUhdWmwNGm0UZZFVVORNX;wbHJjUW6qaXLpeJMhdVSRUjDrbY5ie2ViYXP0bZZqfHlid3n0bEBKSzVyIH;mJFAvOSCwTR?=M1TnUlE4OzVyOUWz
Drosophila melanogaster S2 cells transfected with N-luc and C-lucMWXGeY5kfGmxbjDBd5NigQ>?M2TWO|ExOCCwTR?=M37ERVQhcA>?NWHEbVV[TE2VTx?=NHm5SYRKdmS3Y3XzJIx2[2moZYLhd4UheHKxdHXpckB1emGwcz3zdIxq[2mwZzDpckBFem:|b4DobYxiKG2nbHHuc4die3SncjDTNkBk\WyuczD0doFve2[nY4Tl[EB4cXSqIF6tcJVkKGGwZDDDMYx2[w>?M4HqPVE4OTJ6Mk[y
Human mixed lymphocyteMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2\r[VUhdk1?MVjEUXNQMVPJR|UxRTFwNjDuUU4>M3LOTlE3OTh3OE[1
Lewis rat lymph node cellsMlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXvTWHc{PSEQvF2=NVjCUGU2TE2VTx?=M1jUdmlEPTB;Mj62JO69VQ>?NELocZYyPjF6NUi2OS=>
cells from the thymus of normal BALB/c miceMXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NU\odphROTBibl2=NHO2U4I4OiCqMonkSG1UVw>?Mny1TY5pcWKrdIOgcJlueGixcILvcIln\XKjdHnvckApVEGIKTD3bZRpKEmFNUCgc4YhOyCwTR?=NV3Jdo8{OTByMkG5OFg>
MRK-nu-1NGfncmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVjGUWJ[UUN3ME2wMlg1PSCyTR?=M4LpRXNCVkeHUh?=
OCUB-MNG\ZZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoixTWM2OD13LkK0JJBONEjMOJBUSU6JRWK=
SF539MlLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEfMc2pKSzVyPUGxMlYheE1?NXzTclhjW0GQR1XS
ES4NYfadnBET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=Ml7iTWM2OD1{MT61JJBONH;tOWdUSU6JRWK=
RL95-2NFH3[pFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYGy[ZJoUUN3ME2xNFcheE1?MU\TRW5ITVJ?
LC-2-adNIrGZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHztenhKSzVyPUSyN{BxVQ>?NYT0O3NJW0GQR1XS
DaudiNVS0bIwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3W3b2lEPTB;NEO0JJBONEm2O|hUSU6JRWK=
NTERA-S-cl-D1MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoHOTWM2OD12NEOgdG0>M1rUUHNCVkeHUh?=
OS-RC-2NWjL[mRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4DXSWlEPTB;NkWyJJBONWnWNpliW0GQR1XS
VA-ES-BJNIXUe45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mn[xTWM2OD15MkOgdG0>NEWwN3VUSU6JRWK=
GR-STMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MoL5TWM2OD16NE[gdG0>MUHTRW5ITVJ?
SW872NWf6WXk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{T1b2lEPTB;OES2JJBOMXvTRW5ITVJ?
NOS-1NFzTTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIPX[YdKSzVyPUi3NUBxVQ>?NIL1NWNUSU6JRWK=
MC116MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkDJTWM2OD17OEWgdG0>MoPMV2FPT0WU
NCI-H1355MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHvKNJlKSzVyPUGuNFEhdk1?NW\3d2J2W0GQR1XS
RPMI-8226M2qwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGDjSFFKSzVyPUGuNVkhdk1?NHjrfYNUSU6JRWK=
TE-15MlzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmLjTWM2OD1zLkO2JI5ONIf2XlhUSU6JRWK=
Ramos-2G6-4C10NXq3[nlET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoDlTWM2OD1zLkS2JI5OMkf4V2FPT0WU
KU812M3ezOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NF[2N5VKSzVyPUKuNFEhdk1?NX\ucnhNW0GQR1XS
EW-1NEXte4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlTkTWM2OD1{LkG3JI5ONY\3XXdsW0GQR1XS
KS-1NXniNVh4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4W2UmlEPTB;Mj60OUBvVQ>?NXPHdlZSW0GQR1XS
SK-LMS-1NWLrSpl2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NETCPWFKSzVyPUKuOFkhdk1?M1K5NXNCVkeHUh?=
TGBC1TKBM3XZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEW4dYVKSzVyPUKuOlkhdk1?M1r1TXNCVkeHUh?=
TE-6MoPSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmnaTWM2OD1{Lke3JI5ONVfES21rW0GQR1XS
ETK-1MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn;oTWM2OD1{LkiyJI5OMYHTRW5ITVJ?
BE-13NEDYVVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2D4cmlEPTB;Mj65PUBvVQ>?NXuydnNTW0GQR1XS
A3-KAWMnSyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn74TWM2OD1{Lkm5JI5OMXXTRW5ITVJ?
TE-10MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlLMTWM2OD1|LkOgcm0>NGrpfZRUSU6JRWK=
DOHH-2NGHXdmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1;WdGlEPTB;Mz6zOUBvVQ>?MYHTRW5ITVJ?
ES6M1nIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHvydpVKSzVyPUOuOFMhdk1?MoSzV2FPT0WU
OPM-2MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NInneHFKSzVyPUSuNVUhdk1?M2\CcnNCVkeHUh?=
SH-4NIe0PZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NUPFdlNuUUN3ME20MlM1KG6PNXu2PYJTW0GQR1XS
NB13MnvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NY[4THlsUUN3ME20MlM3KG6PMYPTRW5ITVJ?
HUTU-80MnqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIH4NllKSzVyPUSuOFIhdk1?M2LDZXNCVkeHUh?=
CCRF-CEMNYrOdHo6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NFG2TZVKSzVyPUSuPVQhdk1?MXfTRW5ITVJ?
TGBC24TKBMlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnXZTWM2OD13LkWxJI5OMWHTRW5ITVJ?
697NX;BO4Z1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYTJR|UxRTZwMkigcm0>MmTqV2FPT0WU
J-RT3-T3-5MkjkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnSwTWM2OD14LkS2JI5OMVnTRW5ITVJ?
KALS-1NXW5Unk5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX7JR|UxRTZwNU[gcm0>NULIN45VW0GQR1XS
no-10NFLGSVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV3JR|UxRTdwMkmgcm0>M2q3THNCVkeHUh?=
SK-NEP-1M3e0SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M{i2cmlEPTB;OD63PUBvVQ>?MWfTRW5ITVJ?
L-540NIewOWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXkTWM2OD1zMD60NkBvVQ>?M2XzcXNCVkeHUh?=
JiyoyeP-2003M{PyW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M3W0XGlEPTB;MUCuPVQhdk1?M2faRnNCVkeHUh?=
HHMly3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUL5S4MyUUN3ME2xNU4{QSCwTR?=M2ftZXNCVkeHUh?=
SRNEDYUlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGC4VpZKSzVyPUGxMlQ2KG6PMljjV2FPT0WU
QIMR-WILNInrZZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{[4O2lEPTB;MUGuPFUhdk1?NHLiN5dUSU6JRWK=
A4-FukNYfMOmk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEXtS25KSzVyPUGzMlEzKG6PNVe2VZJNW0GQR1XS
CESSNUjlTZNrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX7IOHF5UUN3ME2xN{4yOyCwTR?=NYrpZW5OW0GQR1XS
KE-37M2Dlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NILENXlKSzVyPUG2MlA4KG6PNXrHUWdIW0GQR1XS
SK-UT-1NEfPZnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmjXTWM2OD1zNj64NUBvVQ>?MWTTRW5ITVJ?
SIG-M5NGS5T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGLybGNKSzVyPUG3MlI2KG6PNWrCdFZDW0GQR1XS
HTNHPLcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2XPc2lEPTB;MUeuOkBvVQ>?M3\kU3NCVkeHUh?=
DELMX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4CxRWlEPTB;MUeuPVkhdk1?M3PTdnNCVkeHUh?=
SK-PN-DWMXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTJyLkKzJI5OMWPTRW5ITVJ?
RPMI-8402MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1nxXGlEPTB;MkGuO|chdk1?MWDTRW5ITVJ?
RPMI-6666M2DNVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkPKTWM2OD1{ND60NkBvVQ>?MUfTRW5ITVJ?
NCI-H720M{HuZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2\ZV2lEPTB;MkWuOFEhdk1?NF;yflhUSU6JRWK=
EW-16MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlPwTWM2OD1{Nj64O{BvVQ>?M3\o[HNCVkeHUh?=
BL-70NXjYUWtLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfFZpJ6UUN3ME2yPE4{QCCwTR?=NVXOVZVjW0GQR1XS
SF126MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NV3DT|RHUUN3ME2zNE4{QCCwTR?=NXW0SXA5W0GQR1XS
BC-1M1PyN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M17mfmlEPTB;M{GuNlYhdk1?NFHQeFNUSU6JRWK=
MHH-PREB-1MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWP5b4FUUUN3ME2zNk41PCCwTR?=M1LQe3NCVkeHUh?=
A101DNGLBeZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonhTWM2OD1|Mj62NkBvVQ>?MmfuV2FPT0WU
NMC-G1NGWxbopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVXJR|UxRTN|Lk[3JI5OMVnTRW5ITVJ?
LB1047-RCCMXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHjR[|NKSzVyPUO0MlY6KG6PMVPTRW5ITVJ?
EM-2Mli1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXT6O5RDUUN3ME2zPE42OyCwTR?=NWn4SIhIW0GQR1XS
COLO-684NE\wb2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MonrTWM2OD1|OT64JI5OM1fjV3NCVkeHUh?=
BeckerNGjzPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVnrVnJwUUN3ME20NU4xPSCwTR?=MVrTRW5ITVJ?
BL-41NWfpZWQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MW\JR|UxRTR|Lk[2JI5OM1;KO3NCVkeHUh?=
MDA-MB-134-VIMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF[yW5hKSzVyPUS0MlAzKG6PMV3TRW5ITVJ?
L-363M{jXU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXH6Rm9EUUN3ME20OE44OyCwTR?=MmG0V2FPT0WU
ECC4NIewOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MWrJR|UxRTR2Lke4JI5OMXjTRW5ITVJ?
A388M3zUXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUjJR|UxRTR2LkiyJI5OMmDPV2FPT0WU
HELMnXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mlu4TWM2OD12OT63PUBvVQ>?M{THc3NCVkeHUh?=
RKOM2DJfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWnDNpoxUUN3ME21NE4zQSCwTR?=M1TnOXNCVkeHUh?=
KINGS-1NWLCbGpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NE\mZXNKSzVyPUWxMlU2KG6PNUf0b3NKW0GQR1XS
EB-3MnnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MojpTWM2OD13Mj62O{BvVQ>?Mo\LV2FPT0WU
ARH-77M1fvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MmPQTWM2OD13Mj64JI5ONIDk[nFUSU6JRWK=
GCIYNIrUNGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MnXjTWM2OD13Mz60OkBvVQ>?MWHTRW5ITVJ?
NCI-H1304NIi2bZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NG\6NGJKSzVyPUW3MlIzKG6PNHLhNXNUSU6JRWK=
KARPAS-299MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVLweVFYUUN3ME22NU45OiCwTR?=MUHTRW5ITVJ?
IA-LMMlPzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIfDU3NKSzVyPU[4MlE{KG6PNWLISm5[W0GQR1XS
GI-1Mnu2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXPs[Jl6UUN3ME23NE4{QSCwTR?=MVHTRW5ITVJ?
TE-11NFTrfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYrxU4drUUN3ME23O{4yPyCwTR?=NGPTZW1USU6JRWK=
LS-411NNWHDXXVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXvJR|UxRTd5LkW3JI5ONXzQXmtvW0GQR1XS
no-11NH\CeGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXrsT|NsUUN3ME24N{4zPCCwTR?=MUXTRW5ITVJ?
MV-4-11MlftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NUPHeotGUUN3ME24N{44OyCwTR?=MXfTRW5ITVJ?
BV-173NUHjN49pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MX\JR|UxRTh|Lkm3JI5OMXfTRW5ITVJ?
CMKMkm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHzzNlNKSzVyPUi0MlE3KG6PNEjRZ|dUSU6JRWK=
LC4-1Mn[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnO1TWM2OD16Nj63NkBvVQ>?MVnTRW5ITVJ?
COR-L279NXK2R5lZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVfxeXRTUUN3ME24O{4zPSCwTR?=MknkV2FPT0WU
NCI-H209NYPMPY82T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVPERoc1UUN3ME24O{41OSCwTR?=MoDGV2FPT0WU
RajiM{PpcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjWTWM2OD16OT63NkBvVQ>?NYrWbGRuW0GQR1XS
LB996-RCCNWnQPZpET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{LU[mlEPTB;OUOuOFMhdk1?NHe4fohUSU6JRWK=
NCI-H526NHXqcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NXfoO5REUUN3ME25N{42QSCwTR?=MYfTRW5ITVJ?
KGNNIPTNHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mmm4TWM2OD17Nj6yPUBvVQ>?Mny3V2FPT0WU
MOLT-4M1v0N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlTzTWM2OD17Nj63PUBvVQ>?NXW1OoYzW0GQR1XS
PF-382NY[5SXhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NX\uVpRjUUN3ME25Ok44QSCwTR?=NELQW|RUSU6JRWK=
BC-3M3XxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NX7zb4tIUUN3ME25PU4yQCCwTR?=NXjTRVNEW0GQR1XS
KARPAS-422NXnHNFF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjWOJJHUUN3ME2xNFIvODlibl2=MV\TRW5ITVJ?
SBC-1MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIrJbJJKSzVyPUGwO{44PSCwTR?=MWnTRW5ITVJ?
LC-1FNWXkfIF1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWDmOpV2UUN3ME2xNFgvODVibl2=M1G0dHNCVkeHUh?=
GB-1M2LpRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1TGTGlEPTB;MUC5MlAzKG6PMoHCV2FPT0WU
SNB75MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NEDhNoZKSzVyPUGxPU43QSCwTR?=M{\uNHNCVkeHUh?=
BB65-RCCMWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4PyOWlEPTB;MUG5Mlk{KG6PMV7TRW5ITVJ?
NCI-N87M3XMSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M33JZ2lEPTB;MUKxMlk5KG6PM{TnVHNCVkeHUh?=
IST-MEL1MkLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3r6e2lEPTB;MUKyMlM5KG6PNUPLNGhjW0GQR1XS
HOP-62M4rDR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHLtd|dKSzVyPUGyOk45QSCwTR?=M1myRnNCVkeHUh?=
ACNNXPMeGoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVnJR|UxRTF2Nj63OUBvVQ>?MojyV2FPT0WU
DMS-114MlvPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NH[4NIVKSzVyPUG1NE43PyCwTR?=MX3TRW5ITVJ?
MLMANF3iUY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYnJR|UxRTF3OT64PEBvVQ>?MVfTRW5ITVJ?
HT-144Mm\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7xNZlKSzVyPUG2OU41OyCwTR?=NFXxUlZUSU6JRWK=
C2BBe1MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn7CTWM2OD1zNkeuO|Yhdk1?MWPTRW5ITVJ?
L-428MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXTXZnhXUUN3ME2xO|cvPyCwTR?=Ml;KV2FPT0WU
DU-4475MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4C0RmlEPTB;MUi3MlY5KG6PMWjTRW5ITVJ?
CP67-MELMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MkfCTWM2OD1zOUmuN|ghdk1?M1jiXHNCVkeHUh?=
MEG-01NEjmOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYTJR|UxRTJyMT65OkBvVQ>?MXnTRW5ITVJ?
IST-SL2NHTkeXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTJyOD62N{BvVQ>?MUXTRW5ITVJ?
ES8NXnOXHhST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYHJR|UxRTJ{NT65OEBvVQ>?Ml\MV2FPT0WU
COLO-800MkP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYL0W3N[UUN3ME2yN|UvOjhibl2=NHrZWlBUSU6JRWK=
MFH-inoNWrNO|FzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTJ|NT64OEBvVQ>?M3LkU3NCVkeHUh?=
OVCAR-4NGHwT5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M2\rVmlEPTB;MkO3MlI1KG6PM3X1ZnNCVkeHUh?=
PSN1MlrzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYCzTI5LUUN3ME2yOFIvPzFibl2=NXj0bZdzW0GQR1XS
EW-12M{HMT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkXQTWM2OD1{NEOuNUBvVQ>?NYfUNJdOW0GQR1XS
HCC1599NIfNO3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTJ4MT60O{BvVQ>?MYDTRW5ITVJ?
SJSA-1MluzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MnrxTWM2OD1{N{GuOFYhdk1?M{LyRnNCVkeHUh?=
ST486MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmK2TWM2OD1{OU[uNVQhdk1?NFHuUJhUSU6JRWK=
NOMO-1NXq1cJNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M33MVGlEPTB;M{CwMlIyKG6PNXLOS|RlW0GQR1XS
MN-60M3LnWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MojwTWM2OD1|MEWuN|Ihdk1?M3;PWnNCVkeHUh?=
HCC1187NXHjRpZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYjJR|UxRTNyNz6yOUBvVQ>?NVn5[nRpW0GQR1XS
SW982NHf3eVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWHrNHBWUUN3ME2zNVQvPzVibl2=MVfTRW5ITVJ?
LB647-SCLCNYnOT5oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M{\DfGlEPTB;M{K4MlcyKG6PM{DOV3NCVkeHUh?=
HC-1NXzCb4JsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWfJR|UxRTN|NT61JI5ONGHlUIdUSU6JRWK=
EHEBM{PaR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX\JR|UxRTN|Nz61NkBvVQ>?M1XnVXNCVkeHUh?=
TURMm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4iyemlEPTB;M{[zMlk2KG6PMWLTRW5ITVJ?
LU-139M33IcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mor5TWM2OD1|N{iuNFIhdk1?NFHL[VhUSU6JRWK=
NB1MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NWrx[Wx4UUN3ME2zPFQvPDVibl2=MVXTRW5ITVJ?
BB30-HNCNGjMdINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGHVdWNKSzVyPUO4PE4{OiCwTR?=MX3TRW5ITVJ?
HAL-01NYPPOpdJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmTITWM2OD1|OEmuNlYhdk1?NEjYNG5USU6JRWK=
K5MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXn6empQUUN3ME20NVEvOzdibl2=NVHiZVF[W0GQR1XS
MZ2-MELMkPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NWGwUoVUUUN3ME20NVMvPjRibl2=MofRV2FPT0WU
RXF393Mnn6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVjZOIVKUUN3ME20NVYvPDVibl2=M1XCS3NCVkeHUh?=
NCI-H1648NYnyXXl{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVzxdnV3UUN3ME20NVcvPTNibl2=NXr3c282W0GQR1XS
TE-12MkLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NV3LT3VsUUN3ME20N|QvOjZibl2=MUjTRW5ITVJ?
EoL-1-NXj6OGFHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoS4TWM2OD12M{euPVghdk1?NHLlS|NUSU6JRWK=
JARMn\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MX\JR|UxRTR|OD62NkBvVQ>?MmrGV2FPT0WU
DSH1M2fGW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkLrTWM2OD12NUiuPVEhdk1?M361OXNCVkeHUh?=
NCI-H187NYHBTFNmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEfxeXJKSzVyPUS2Nk45OSCwTR?=M1WzZ3NCVkeHUh?=
HCE-4MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\ReZFKSzVyPUS3O{43PiCwTR?=M2rnV3NCVkeHUh?=
8-MG-BANWe2UIRXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWrSdHpQUUN3ME21PFEvPTJibl2=M4LhcHNCVkeHUh?=
KLEMoXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmrmTWM2OD13OEWuNkBvVQ>?Mn7WV2FPT0WU
KNS-42NI[2R|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoTsTWM2OD13OE[uPFEhdk1?NX6w[3N5W0GQR1XS
MSTO-211HMVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGDGVZhKSzVyPU[wPU44PCCwTR?=M1zhbHNCVkeHUh?=
GDM-1NYPUc2RDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUewbGIxUUN3ME22NVQvODlibl2=NFfGZ2NUSU6JRWK=
TE-1NHjLOpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDpTWM2OD14NE[uNVIhdk1?MUDTRW5ITVJ?
BT-474M2fYUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYjVUlVxUUN3ME22OFcvODZibl2=NUXBUllkW0GQR1XS
KARPAS-45M2LtVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NXnVNIZpUUN3ME22OFcvPiCwTR?=M3vvT3NCVkeHUh?=
MOLT-16MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVS3U2RLUUN3ME22OFcvQTNibl2=NXLkPWgxW0GQR1XS
KURAMOCHIM{H2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUXJR|UxRTZ3Nz61NUBvVQ>?NI\UTFVUSU6JRWK=
K-562M2nCTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTZ4OT61NUBvVQ>?NUiyZmc{W0GQR1XS
EKVXNW\UU2ZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PPNWlEPTB;NkeyMlcyKG6PM1PtTXNCVkeHUh?=
GAKM{HC[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NWDCRpZRUUN3ME22O|UvOyCwTR?=NX;Ucm96W0GQR1XS
NCI-SNU-5NYfs[5ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVHJR|UxRTZ7MD6wNUBvVQ>?NGKwWFFUSU6JRWK=
NCI-H2126MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MlXHTWM2OD15Mk[uPFchdk1?M{HHZXNCVkeHUh?=
CTV-1MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnqzTWM2OD15NESuPUBvVQ>?MXrTRW5ITVJ?
SW962M{Pudmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M12wXmlEPTB;N{S4MlQ1KG6PM2rGWnNCVkeHUh?=
MONO-MAC-6NXu4[WJKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MULJR|UxRTd3Nj65N{BvVQ>?NWKxU3pGW0GQR1XS
NCI-H748MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3LiV2lEPTB;N{W4Mlk6KG6PMnfxV2FPT0WU
NCI-H524MnfGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{TOTWlEPTB;N{iwMlc{KG6PM4nZZnNCVkeHUh?=
LS-123Ml\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mn[5TWM2OD15OUWuOlkhdk1?M{HidHNCVkeHUh?=
NB7MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M3;4Z2lEPTB;OEG0MlE1KG6PMVLTRW5ITVJ?
LS-1034NGi4bppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF;0PXRKSzVyPUiyPE46QCCwTR?=M1;vfnNCVkeHUh?=
TE-5NFXMVGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYfNNmZNUUN3ME24PFMvPTZibl2=MUnTRW5ITVJ?
A704MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmjpTWM2OD16OUmuNVUhdk1?M4q4SnNCVkeHUh?=
TK10NGmzOJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIjIXlBKSzVyPUmxOk4xOyCwTR?=MVnTRW5ITVJ?
NCI-H345NH7rd3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVrZbVRSUUN3ME25OFMvOjJibl2=M1zvXHNCVkeHUh?=
CGTH-W-1NULO[4pbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmfITWM2OD17NEiuNVMhdk1?M3zrbHNCVkeHUh?=
NCI-H510AMVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2XhemlEPTB;OUi1MlEzKG6PNYTsUYVyW0GQR1XS
NCI-H1963MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGHLUnBKSzVyPUGuNFMzQTJizszNMoXSV2FPT0WU
SCC-3NX32R|ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnuzTWM2OD1zLkCzOFE1KM7:TR?=M4fq[XNCVkeHUh?=
EW-11NV3FUlJOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUD3cosxUUN3ME2xMlA5PzR|IN88US=>MmfTV2FPT0WU
CPC-NM1PzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1rTWmlEPTB;MT6wPFgh|ryPMWjTRW5ITVJ?
NCI-H1417NVjEeGl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NGLS[|VKSzVyPUGuNVIzPiEQvF2=NEPYOVZUSU6JRWK=
DG-75NXS0N|c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTFwMU[yPFUh|ryPMlXmV2FPT0WU
HD-MY-ZNYjNSINYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NU\Ic5pTUUN3ME2xMlE3PDF4IN88US=>Mnv1V2FPT0WU
ATN-1MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Ml3tTWM2OD1zLkK2NlA6KM7:TR?=M1jBVXNCVkeHUh?=
KM-H2NFjFbY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHS0Z4ZKSzVyPUGuNlY1ODhizszNMlu2V2FPT0WU
NCI-H2081NWrtcmRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmLhTWM2OD1zLkK2OlM4KM7:TR?=NEHOcXdUSU6JRWK=
HL-60M4W4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NITtR3JKSzVyPUGuNlY6PTlizszNM1HQT3NCVkeHUh?=
DBNHPOVWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfRTWM2OD1zLkK3NlQzKM7:TR?=NY\ZTo1EW0GQR1XS
NCI-H1522M4HCc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7Mn76TWM2OD1zLkK4PFg4KM7:TR?=MlzyV2FPT0WU
AM-38MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MV\JR|UxRTFwM{C3NkDPxE1?NEDn[|NUSU6JRWK=
NCI-H446NIHLd2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYHJR|UxRTFwM{KxNlEh|ryPNHzMbFBUSU6JRWK=
SU-DHL-1MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MW\JR|UxRTFwM{K4NFEh|ryPMlHPV2FPT0WU
NH-12M1LwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGLXSJNKSzVyPUGuN|Y{PzRizszNMWfTRW5ITVJ?
DMS-79MoLpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?Mle0TWM2OD1zLkO2PFY3KM7:TR?=MV;TRW5ITVJ?
NCI-H716NVjFSmdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlLaTWM2OD1zLkO4PVg3KM7:TR?=M3vnVnNCVkeHUh?=
ML-2NWezWZoyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUe4dmhWUUN3ME2xMlQyPTJ7IN88US=>Mke4V2FPT0WU
NB10M3i3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NEW3TZpKSzVyPUGuOFY3OzJizszNM3XSfXNCVkeHUh?=
ONS-76MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MkjjTWM2OD1zLkWzOVY6KM7:TR?=M3jJXXNCVkeHUh?=
LOUCYNHqyRplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmXlTWM2OD1zLkW0OlU4KM7:TR?=NVPXXlU4W0GQR1XS
SCLC-21HNXvMTm5kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnzMTWM2OD1zLkW4OVgzKM7:TR?=NH33OVlUSU6JRWK=
TGWMnXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MU\JR|UxRTFwNkO5O|Uh|ryPMnnrV2FPT0WU
LXF-289M3LPZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHPGNZpKSzVyPUGuO|MzPjhizszNNH7kTXFUSU6JRWK=
BB49-HNCNUGyZpJmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M3fiZWlEPTB;MT63N|U5PiEQvF2=M{jmbnNCVkeHUh?=
NCI-H747MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1XTbmlEPTB;MT63OVM1PiEQvF2=NXPXcXliW0GQR1XS
LU-165MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVfJR|UxRTFwOES5PFYh|ryPM1;tSHNCVkeHUh?=
OMC-1M1Pkbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MVjJR|UxRTFwOUWwOlYh|ryPMnu2V2FPT0WU
RCC10RGBMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MnLoTWM2OD1zLkm1PFE4KM7:TR?=NH31ToVUSU6JRWK=
SW684MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NFvTbHBKSzVyPUGuPVYxQTlizszNMXvTRW5ITVJ?
TE-8NEPrXXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFH3S|dKSzVyPUKuNFU2PTlizszNNX7scZZnW0GQR1XS
SK-N-DZM3\EUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWLJR|UxRTJwMUOyO|Qh|ryPNG\uOphUSU6JRWK=
EVSA-TMU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXW4Om4xUUN3ME2yMlE4OzF3IN88US=>NEO4[4JUSU6JRWK=
KASUMI-1MlnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHz5c3VKSzVyPUKuNVg5OTVizszNNIDRWo1USU6JRWK=
NKM-1M1;sNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGrHWoZKSzVyPUKuNlU1PzJizszNNGrESZNUSU6JRWK=
CAL-148NWHQd5dsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MWjJR|UxRTJwM{O2NVQh|ryPM4fyfHNCVkeHUh?=
NCI-H64NFPGSG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MYjJR|UxRTJwM{SyN|Ih|ryPNIfIZWpUSU6JRWK=
KNS-81-FDM4XufGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFXDfWJKSzVyPUKuN|Y3OiEQvF2=NF3wbY5USU6JRWK=
KM12MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1PWdGlEPTB;Mj60NFg{QSEQvF2=MX\TRW5ITVJ?
SW954MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mm\CTWM2OD1{LkS3O|c6KM7:TR?=NIHVWGVUSU6JRWK=
NCI-H1395MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NUPpZXZDUUN3ME2yMlUzPjR3IN88US=>M1z1WnNCVkeHUh?=
DJM-1NXPWUGwzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1fyO2lEPTB;Mj62NFY{KM7:TR?=NG\DSGtUSU6JRWK=
COLO-668M2TGbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MUfJR|UxRTJwOEK2PVUh|ryPNWXOWlN4W0GQR1XS
NCI-H1436NVPicWFqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTJwOEW2NVUh|ryPNYLLVY82W0GQR1XS
LB2241-RCCNYPX[Zo1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MmjZTWM2OD1{Lki2PFM6KM7:TR?=NGDDSpRUSU6JRWK=
GT3TKBMmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NF7lVHBKSzVyPUKuPFkxPTVizszNNWLQdYw1W0GQR1XS
COLO-824MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1HqcmlEPTB;Mj64PVc3QCEQvF2=MkDIV2FPT0WU
ES1MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NXzzXHlFUUN3ME2yMlg6QDd7IN88US=>M3nvUXNCVkeHUh?=
LB771-HNCM4HSUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MlmzTWM2OD1{LkmwPVQ3KM7:TR?=MlvuV2FPT0WU
GI-ME-NNWj1WIp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NYDiVGw1UUN3ME2zMlAxQTB2IN88US=>NU\EbWRyW0GQR1XS
NALM-6Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NEHBR5VKSzVyPUOuNFA6OzNizszNNXPjSG15W0GQR1XS
LU-134-AM1Tj[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTNwMEW0NlUh|ryPNEX1VFFUSU6JRWK=
DMS-153M3\wT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NV7mUHVLUUN3ME2zMlA2QDJ2IN88US=>NV3qeXREW0GQR1XS
MZ1-PCNIDuVmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MUjJR|UxRTNwMEmwO|gh|ryPMmrHV2FPT0WU
NCI-H1155MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGrNWXFKSzVyPUOuNVE3OSEQvF2=MUTTRW5ITVJ?
CAS-1M{izcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYnGe2R5UUN3ME2zMlE{PzB5IN88US=>MnfwV2FPT0WU
D-502MGMWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NHfUdYlKSzVyPUOuNVQ{QSEQvF2=M{PEdHNCVkeHUh?=
NCI-H2141M4WzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NVvuZlFvUUN3ME2zMlE4PDV{IN88US=>MnXNV2FPT0WU
NB6MnnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MVPJR|UxRTNwMUiyOVkh|ryPMnraV2FPT0WU
NCCITMYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVHjTXh4UUN3ME2zMlIyQDB7IN88US=>NVfENotiW0GQR1XS
NB69NX34NGFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUDNRpVwUUN3ME2zMlMyQDlzIN88US=>NYnGR2xTW0GQR1XS
JVM-2M1HCcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MnHQTWM2OD1|LkO2OFM{KM7:TR?=NYHFdmR7W0GQR1XS
K052MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXjJR|UxRTNwM{e5Olgh|ryPNFT6[ZdUSU6JRWK=
HCC2157M2TI[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2CybmlEPTB;Mz61N|IzQCEQvF2=NHLsfY5USU6JRWK=
KMOE-2M2C1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NFzl[WZKSzVyPUOuOVQzPDJizszNNV3qSWMyW0GQR1XS
SF268MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NG\hWWVKSzVyPUOuO|E2PTRizszNMUfTRW5ITVJ?
CHP-126MmnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M{j5XGlEPTB;Mz63OlQ2QCEQvF2=NV\WVWFJW0GQR1XS
CP66-MELMn3CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NW\iUFNuUUN3ME2zMlc6ODl2IN88US=>NHXnPJBUSU6JRWK=
NCI-H69MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFOyblNKSzVyPUSuNFE6OzZizszNNHTKdYVUSU6JRWK=
A253MljtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2rnVmlEPTB;ND6wNlExOSEQvF2=MlnHV2FPT0WU
NB14NFvFNG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWW2XWNYUUN3ME20MlExPDd7IN88US=>MmHEV2FPT0WU
NCI-H1694MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MYrJR|UxRTRwMUOxNVIh|ryPM3rSeXNCVkeHUh?=
NCI-H2196M1LuW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MX7JR|UxRTRwMUexOlkh|ryPM3LiO3NCVkeHUh?=
TE-9MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NHvR[ZBKSzVyPUSuNVc2QDJizszNMVrTRW5ITVJ?
D-283MEDNFzZeVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NIfNV29KSzVyPUSuNVg5PCEQvF2=M{LuSHNCVkeHUh?=
OCI-AML2NYnkUGhUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1jYXWlEPTB;ND6xPVQ5QSEQvF2=NUTmdIJGW0GQR1XS
D-263MGNV;B[W1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NILnW|FKSzVyPUSuNlI6PjFizszNMVnTRW5ITVJ?
MPP-89Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2SzOGlEPTB;ND6yO|MxPCEQvF2=M1O2bHNCVkeHUh?=
LAMA-84NYPvO2JZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUewNYNrUUN3ME20MlMxPDJzIN88US=>NWXK[ZJIW0GQR1XS
LB373-MEL-DNEK5fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MkHUTWM2OD12LkO2O|g6KM7:TR?=NIDLTphUSU6JRWK=
UACC-257M4\GS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7NGP6NotKSzVyPUSuN|k2OzRizszNM{HpZnNCVkeHUh?=
MC-CARNIHze5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGTLeJZKSzVyPUSuOFM6QSEQvF2=MmfpV2FPT0WU
COLO-320-HSRM3T2Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NUnzNWhbUUN3ME20MlQ1PDJ5IN88US=>M33UVXNCVkeHUh?=
P30-OHKMVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITpUZBKSzVyPUSuOlY2QDFizszNNV7KOnZQW0GQR1XS
UACC-812MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mn3qTWM2OD12Lk[5NVYyKM7:TR?=NVnMXIlvW0GQR1XS
CTB-1MoPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGDQfW9KSzVyPUSuO|E2PTVizszNMmjhV2FPT0WU
ALL-POMm\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NIjFb41KSzVyPUSuPFQxPzdizszNMWjTRW5ITVJ?
SK-MEL-2M4XOZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MkjTTWM2OD12Lki2PVU2KM7:TR?=MXHTRW5ITVJ?
TC-YIKNEHGToFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MlXrTWM2OD12Lkm3PVQzKM7:TR?=M3nIRnNCVkeHUh?=
NCI-H1882MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVXJR|UxRTVwMEKwNFEh|ryPMkP0V2FPT0WU
MHH-CALL-2NWnLeY5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MXTJR|UxRTVwMEWwOFIh|ryPNFnmSnpUSU6JRWK=
U-87-MGNInrUIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmK1TWM2OD13LkC5OFY3KM7:TR?=MmPzV2FPT0WU
NCI-H1092MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M2X1RWlEPTB;NT6yOlU2PSEQvF2=NHPkSY9USU6JRWK=
TE-441-TNFXxOHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MoDyTWM2OD13LkK3PFIh|ryPMVXTRW5ITVJ?
SK-MEL-1NGLvW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVLJR|UxRTVwMkmwOFQh|ryPMUPTRW5ITVJ?
EW-22MkjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M1;HOGlEPTB;NT6yPVQ3PiEQvF2=M3:0Z3NCVkeHUh?=
MZ7-melMV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M3:5S2lEPTB;NT60NFY6OSEQvF2=MWPTRW5ITVJ?
LP-1NX;vTG1XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NUnzcpFzUUN3ME21MlQyOjlzIN88US=>MVXTRW5ITVJ?
NCI-SNU-16NVTDV|duT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MoXFTWM2OD13Lk[0NFc1KM7:TR?=Ml;QV2FPT0WU
LU-65NIrFPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGfoWJVKSzVyPUWuO|Y{PzNizszNM1T1dHNCVkeHUh?=
CW-2M1fGNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1ixOWlEPTB;NT64OVk2QSEQvF2=M3[5UHNCVkeHUh?=
WSU-NHLM2HWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NHi2dZJKSzVyPUWuPVUyPzRizszNMoW3V2FPT0WU
IST-MES1NU\oU|hbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NISz[IxKSzVyPUWuPVU1PDNizszNMXzTRW5ITVJ?
U-266M{n1[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWnJR|UxRTVwOUiyNFIh|ryPM1vwZnNCVkeHUh?=
TALL-1MlXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MoT3TWM2OD14LkG0Olg5KM7:TR?=M2rxcHNCVkeHUh?=
Calu-6NETIOIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWPVb203UUN3ME22MlE2OzF4IN88US=>MmfUV2FPT0WU
MMAC-SFNFTteo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NF\WVWFKSzVyPU[uNVg2PTZizszNNGDJcHpUSU6JRWK=
NCI-H82NX3GeI5MT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MlrkTWM2OD14LkKwOFg6KM7:TR?=MYDTRW5ITVJ?
RS4-11NYKxeIVvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NV\yNXVJUUN3ME22MlI2QDl5IN88US=>MlXtV2FPT0WU
SNU-C2BMVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NFSwZm9KSzVyPU[uOFA6PjlizszNNGP6S2VUSU6JRWK=
BOKUMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NGjpXmFKSzVyPU[uOFc2QTdizszNNXnBVphCW0GQR1XS
C8166MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M1j4dGlEPTB;Nj61OVkyOiEQvF2=MYrTRW5ITVJ?
D-247MGNXfTXWtwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVvSUI9nUUN3ME23MlA1OzR5IN88US=>M3jSZnNCVkeHUh?=
EW-18NW[2[XZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MY\JR|UxRTdwMEeyPVIh|ryPNWq2[HRWW0GQR1XS
KG-1MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWfJR|UxRTdwNkK3N|gh|ryPM2LTW3NCVkeHUh?=
REHNF\RTnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXPJR|UxRTdwNkixNFkh|ryPNYr2[|VIW0GQR1XS
U-698-MNHKwb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmDnTWM2OD15Lki0N|E2KM7:TR?=NFnZSlhUSU6JRWK=
KP-N-RT-BM-1MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MmqxTWM2OD15LkmzNFI6KM7:TR?=NVHtfZZlW0GQR1XS
MS-1NIPlUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=Mnq5TWM2OD15Lkm2NFQyKM7:TR?=NY[1[GZxW0GQR1XS
SNU-C1MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MVnJR|UxRTdwOUixPVIh|ryPNXHnb4lNW0GQR1XS
SK-MM-2MnTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NGrMNG5KSzVyPUiuNlYxPjVizszNMXfTRW5ITVJ?
LAN-6NWW1Z2p3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEL1PIdKSzVyPUiuN|AxODFizszNMXjTRW5ITVJ?
NEC8M3u4XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7M2XaT2lEPTB;OD6zNFY6OSEQvF2=NGm2ZoJUSU6JRWK=
NCI-H1770MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MWXJR|UxRThwM{iwNFIh|ryPMYTTRW5ITVJ?
D-336MGMkHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NYflW2x[UUN3ME24MlQxOTF4IN88US=>NGLL[VdUSU6JRWK=
COLO-829NYW0XHZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MUTJR|UxRThwNEi4O|kh|ryPMmLDV2FPT0WU
LS-513MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NYHsNnE4UUN3ME24MlU6PTl7IN88US=>NH;INWdUSU6JRWK=
YTNXnBT3g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NEPnW|VKSzVyPUiuOlI1OjdizszNMYTTRW5ITVJ?
EW-24NWrib4hHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NVTYV|AxUUN3ME24Mlc3PTRizszNMkXjV2FPT0WU
IST-SL1NH\qN2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NGXXZpJKSzVyPUiuPFY2PDNizszNMXTTRW5ITVJ?
CA46NGfzSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLLeJN2UUN3ME24Mlk2ODl6IN88US=>MXfTRW5ITVJ?
NCI-H1838MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M4fMeWlEPTB;OD65PFYxOiEQvF2=NVfGdJM2W0GQR1XS
NCI-H719NIDMNYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NYL5bIdPUUN3ME25MlI2Ojd7IN88US=>MV;TRW5ITVJ?
HCE-TNF7BZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXLJR|UxRTlwM{C4OVEh|ryPNVzoPGU4W0GQR1XS
A498NELNN3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFS1cGVKSzVyPUmuN|YyOjRizszNMXTTRW5ITVJ?
LB831-BLCNXPkNYNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M4PqS2lEPTB;OT63OlUzOSEQvF2=MkWzV2FPT0WU
SKM-1NX;pdFJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M2jrXWlEPTB;OT64OVk3OyEQvF2=M4mzfXNCVkeHUh?=
THP-1NGfkTmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NHHuTpRKSzVyPUmuPVY6OThizszNNGHMPWpUSU6JRWK=
SHP-77NHHJbJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NVLsTllXUUN3ME2xNE41ODdizszNMoLOV2FPT0WU
EW-3NX2zfIFGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkXiTWM2OD1zMD62Nlg6KM7:TR?=MV\TRW5ITVJ?
KY821NWTuPXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NET5dYJKSzVyPUGwMlc3OyEQvF2=MoDHV2FPT0WU
NCI-SNU-1NEDQRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MXzJR|UxRTFzLkCyNVch|ryPM3HqW3NCVkeHUh?=
HCC2218NUnsVoNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NESzU41KSzVyPUGxMlM6QDZizszNMX3TRW5ITVJ?
IM-9NELRPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MVfJR|UxRTFzLkWxNFYh|ryPM{TUenNCVkeHUh?=
NCI-H889NETJcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M1jrcGlEPTB;MUGuOVMyOyEQvF2=M4e2fnNCVkeHUh?=
HDLM-2NHrmO5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M3vKZmlEPTB;MUKuOFE2QSEQvF2=M3;vZnNCVkeHUh?=
LB2518-MELNXH1VIZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MV\JR|UxRTF{Lk[4NVUh|ryPNWHG[GRsW0GQR1XS
NCI-H23NGi4TGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MV7JR|UxRTF|LkK0NlUh|ryPNYqxPZVZW0GQR1XS
NB17NEKzS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NWfJSFJKUUN3ME2xN{41PTd7IN88US=>NX;oPGdlW0GQR1XS
NCI-H322MNXThRY1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MVTJR|UxRTF2LkSwOlgh|ryPM1L4UXNCVkeHUh?=
SUP-T1Ml7rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmXJTWM2OD1zND60NVMh|ryPMkCwV2FPT0WU
ES3M{G5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MWTJR|UxRTF3LkC3NFMh|ryPNX24eXFUW0GQR1XS
ES5NUi1[pd2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MkPBTWM2OD1zNT6wO|g4KM7:TR?=MknxV2FPT0WU
NCI-H1650NXzmZodrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NWjkfmp5UUN3ME2xOU41QTd7IN88US=>MmfCV2FPT0WU
NCI-H226M1y3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7M1z2WGlEPTB;MUWuPFc3QCEQvF2=NHX3Z5VUSU6JRWK=
COR-L88MoLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2jWd2lEPTB;MU[uN|E1KM7:TR?=M33wb3NCVkeHUh?=
SCC-15MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NETMcnFKSzVyPUG2MlM5PjlizszNNGn5fHpUSU6JRWK=
GOTOM{O0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7NYToZ|VnUUN3ME2xOk41Pzl|IN88US=>MmjZV2FPT0WU
SIMAMWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?Mkm0TWM2OD1zNj60PFAzKM7:TR?=NWXVSXRZW0GQR1XS
NCI-H1299MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NF\ie2hKSzVyPUG3MlE2QTFizszNNUK1XVhMW0GQR1XS
NCI-H1581NFfqd45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NFfp[GlKSzVyPUG3MlQzOTlizszNMYTTRW5ITVJ?
MHH-NB-11MlLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?M2K5eWlEPTB;MUeuPVY5OyEQvF2=MWnTRW5ITVJ?
MFM-223MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NITwWXRKSzVyPUG4MlA2OzhizszNMm\QV2FPT0WU
ES7MkjTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MmPvTWM2OD1zOD61OFMyKM7:TR?=M33rbnNCVkeHUh?=
JVM-3NIPscGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=MmfjTWM2OD1zOD63NVch|ryPNFXpRoRUSU6JRWK=
RLNFXqc5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=NX64cINZUUN3ME2yNE4{QDhizszNM2TsdHNCVkeHUh?=
EC-GI-10Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NXX5RnFMUUN3ME2yNU4zODRzIN88US=>NX31epJuW0GQR1XS
LNCaP-Clone-FGCMlrmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?MXPJR|UxRTJzLk[3Olgh|ryPMlfGV2FPT0WU
IMR-5NUjrSpNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NHPJcFVKSzVyPUKxMlg1QTRizszNNYKwfHpKW0GQR1XS
KP-N-YSMVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?NVTleYRwUUN3ME2yNU45PzVizszNMljYV2FPT0WU
Mo-TMW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?M4TTOWlEPTB;MkKuNlE5PSEQvF2=M3jkNXNCVkeHUh?=
NCI-H128MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?MXXJR|UxRTJ|LkW4OVMh|ryPNEDC[|BUSU6JRWK=
RH-1NULGSIg1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MnXPTWM2OD1{Mz63PFY3KM7:TR?=M4DZSHNCVkeHUh?=
NCI-H2171NVX3PZlTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=M1vyRWlEPTB;MkSuNlQ5PSEQvF2=MVfTRW5ITVJ?
RPMI-8866NW[1NJZiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=NXHpeY5UUUN3ME2yOk44PDJizszNMXXTRW5ITVJ?
SK-N-FIMkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?NVKxZXNLUUN3ME2yO{4{QDFzIN88US=>MYfTRW5ITVJ?
LOXIMVINXTRRXdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm=MYDJR|UxRTJ5LkiwOVEh|ryPMUnTRW5ITVJ?
P31-FUJNH7VWppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=M{PtWmlEPTB;M{GuOVM4PCEQvF2=M{fLSnNCVkeHUh?=
KMS-12-PEM2nBWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7MYDJR|UxRTR7LkWzNFIh|ryPNHfCOFNUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]
Features

Protocol(Only for Reference)

Kinase Assay:

[1]

Immunoblotting for the mTOR kinase assay HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr

Cell Assay:

[3]

Cell lines U87-MG, T98G, and U373-MG
Concentrations Dissolved in DMSO, final concentrations ~25 μM
Incubation Time 72 hours
Method

Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.

Animal Study:

[7]

Animal Models Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
Formulation Dissolved in solvent solution (0.2% carboxymethylcellulose and 0.25% Tween-80 in sterile H2O)
Dosages ~4 mg/kg/day
Administration Injection i.p.

Conversion of different model animals based on BSA (Value based on data from FDA Draft Guidelines)

SpeciesMouseRatRabbitGuinea pigHamsterDog
Weight (kg)0.020.151.80.40.0810
Body Surface Area (m2)0.0070.0250.150.050.020.5
Km factor36128520
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of resveratrol used for a mouse (22.4 mg/kg) to a dose based on the BSA for a rat, multiply 22.4 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for resveratrol of 11.2 mg/kg.

Rat dose (mg/kg) = mouse dose (22.4 mg/kg) ×  mouse Km(3)  = 11.2 mg/kg
rat Km(6)
1

References

[1] Edwards SR, et al. J Biol Chem, 2007, 282(18), 13395-13401.

[2] Barbet NC, et al. Mol Biol Cell, 1996, 7(1), 25-42.

view more

Clinical Trial Information( data from http://clinicaltrials.gov, updated on 2016-07-30)

NCT Number Recruitment Conditions Sponsor
/Collaborators
Start Date Phases
NCT02240407 Not yet recruiting Pompe Disease University of Florida October 2016 Phase 1
NCT02793544 Not yet recruiting Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblasti  ...more Myelodysplastic Syndrome (MDS)|Chronic Lymphocytic Leukemia (CLL)|Chemotherapy-sensitive Lymphoma|Acute Lymphoblastic Leukemia (ALL)/T Lymphoblastic Lymphoma|Acute Myelogenous Leukemia (AML)|Acute Biphenotypic Leukemia (ABL)|Acute Undifferentiated Leukemia (AUL) Center for International Blood and Marrow Transplant Rese  ...more Center for International Blood and Marrow Transplant Research|National Marrow Donor Program|Resource for Clinical Investigation in Blood and Marrow Transplantation August 2016 Phase 2
NCT02587325 Not yet recruiting Pulmonary Hypertension Aadi, LLC August 2016 Phase 1
NCT02806947 Not yet recruiting Acute GVHD Medical College of Wisconsin|National Heart, Lung, and Bl  ...more Medical College of Wisconsin|National Heart, Lung, and Blood Institute (NHLBI)|National Cancer Institute (NCI)|Blood and Marrow Transplant Clinical Trials Network|National Marrow Donor Program July 2016 Phase 2
NCT02833506 Not yet recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ova  ...more Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma|Stage IIA Fallopian Tube Cancer|Stage IIA Ovarian Cancer|Stage IIB Fallopian Tube Cancer|Stage IIB Ovarian Cancer|Stage IIC Fallopian Tube Cancer|Stage IIC Ovarian Cancer|Stage IIIA Fallopian Tube Cancer|Stage IIIA Ovarian Cancer|Stage IIIA Primary Peritoneal Cancer|Stage IIIB Fallopian Tube Cancer|Stage IIIB Ovarian Cancer|Stage IIIB Primary Peritoneal Cancer|Stage IIIC Fallopian Tube Cancer|Stage IIIC Ovarian Cancer|Stage IIIC Primary Peritoneal Cancer|Stage IV Fallopian Tube Cancer|Stage IV Ovarian Cancer|Stage IV Primary Peritoneal Cancer Roswell Park Cancer Institute|National Cancer Institute (  ...more Roswell Park Cancer Institute|National Cancer Institute (NCI) July 2016 Phase 1

view more

Chemical Information

Download Rapamycin (Sirolimus) SDF
Molecular Weight (MW) 914.18
Formula

C51H79NO13

CAS No. 53123-88-9
Storage 3 years -20℃powder
6 months-80℃in solvent
Synonyms AY 22989,NSC-2260804
Solubility (25°C) * In vitro DMSO 20 mg/mL (21.87 mM)
Water <1 mg/mL (<1 mM)
Ethanol <1 mg/mL (<1 mM)
In vivo 0.5% CMC+0.25% Tween 80 30 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Chemical Name (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

* Indicates a Required Field

Related mTOR Products

  • MHY1485

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021)

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively.

  • Dorsomorphin

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779, NSC 683864)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay.

  • INK 128 (MLN0128)

    INK 128 (MLN0128) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Recently Viewed Items

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) ic50 | Rapamycin (Sirolimus) price | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) solubility dmso | Rapamycin (Sirolimus) purchase | Rapamycin (Sirolimus) manufacturer | Rapamycin (Sirolimus) research buy | Rapamycin (Sirolimus) order | Rapamycin (Sirolimus) mouse | Rapamycin (Sirolimus) chemical structure | Rapamycin (Sirolimus) mw | Rapamycin (Sirolimus) molecular weight | Rapamycin (Sirolimus) datasheet | Rapamycin (Sirolimus) supplier | Rapamycin (Sirolimus) in vitro | Rapamycin (Sirolimus) cell line | Rapamycin (Sirolimus) concentration | Rapamycin (Sirolimus) nmr
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Contact Us